Fundraising Fox5AM Ventures — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inStephen Knight(Director)in
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D
Co-investorsAju IB InvestmentCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta VenturesViking Global+10 more
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life SciencesDCVC BioFrazier Healthcare PartnersWestlake Village BioPartners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.